Allogeneic stem cell transplantation for relapsed/refractory aggressive lymphoma with conditioning regimen consisted of fludarabine, iv busulfan, and melphalan (single center prospective trial)
Phase 1
- Conditions
- Relapsed or refractory aggressive non Hodgkin lymphomas (NHL)
- Registration Number
- JPRN-UMIN000013940
- Lead Sponsor
- Department of Hematology Toranomon Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Positive for anti-HIV antibody Active double cancer Severe mental conditions Active infectious disease Known hypersensitivity to drugs to be used in the protocol. Not appropriate for enrollment as judged by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method